Claritev Corporation logo

Claritev Corporation(CTEV)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$26.82
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CTEV

11/13/2026: CTEV (1-star) is currently NOT-A-BUY. Pass it for now.

Claritev Corporation is a healthcare technology and data analytics company that provides payment integrity, cost management, and network solutions to U.S. health insurers. The company's main strengths lie in its deeply embedded payer relationships and historically high operating margins. Its primary investment story centers on growth opportunities in healthcare pricing transparency tools and digital cost-containment. However, key risks include heavy debt leverage, customer concentration, and ongoing regulatory and legal scrutiny regarding its pricing methodologies. The stock may best suit growth or value investors willing to tolerate high volatility, while market participants should closely monitor debt reduction progress and regulatory developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitModerate revenue expansion and digital healthcare product launches offer growth angles, but overall top-line acceleration is gradual.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive Upturn signal and supportive short-term price trend breakouts.
Value investorMixed fitLow valuation multiples appeal to deep-value mandates, but leverage and regulatory risks warrant careful fundamental screening.
Dividend investorWeak fitThe company does not pay regular dividends, focusing cash flow instead on debt management.
Low-risk investorWeak fitHigh equity volatility and regulatory headlines create too much operational risk for risk-averse strategies.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp price swings driven by market sentiment, earnings updates, and legal headlines.
Valuation riskMedium / highMarket pricing reflects skepticism regarding leverage and regulatory headwinds, increasing sensitivity to execution missteps.
Competition risk (AI and healthcare IT competition)MediumIn-house payer solutions and competing data analytics firms pressure pricing power and contract retention.
Business qualityMediumWhile core margins are historically strong, enterprise concentration introduces structural vulnerability.
Dividend incomeLow / noneIncome-focused investors receive no regular cash payout from the stock.
Execution riskMedium / highSuccessfully scaling new transparency tools while managing legacy debt requires flawless operational execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 457.95M USD
Price to earnings Ratio -
1Y Target Price 48.6
Price to earnings Ratio -
1Y Target Price 48.6
Volume (30-day avg) 268.0K shares
Beta 1.05
52 Weeks Range 11.50 - 55.50
Updated Date 11/15/2026
52 Weeks Range 11.50 - 55.50
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -16.41

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -49.13%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CTEV receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CTEV has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+82.7%) is partially offset by weak cash generation (FCF margin -1.3%), moderate revenue growth (+3.7%), weak profitability (net margin -29.4%).

Financial Health Rating

★★★★★
CTEV's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 22.9% of revenue). Liquidity is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CTEV's strongest growth driver at +82.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+3.7%, moderate) and free-cash-flow growth (-16.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 88.5% and approximately 40.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 7.57% supports management-shareholder alignment.

Top 5 Institutional Investors

H&F Corporate Investors VIII, Ltd. 22.79%
Arini Captial Management Ltd 17.99%
Ares Management LLC 10.92%
PUBLIC INVESTMENT FUND 7.51%
Beach Point Capital Management LP 4.40%

Unit Economics (Per $1K Revenue)

★★★★★
CTEV generates approximately $276 of gross profit, $47 of operating income, and $-13 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Negative free cash flow explains the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 23.80%

Quantitative Style Profile

★★★★★
CTEV has a Value-Oriented profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Claims Intelligence & Network ServicesFees and transaction-based revenues generated from reference-based pricing, out-of-network negotiations, and proprietary provider network access.Claritev earns money every time health plans use its networks and pricing tools to lower medical claim payouts.
Payment and Revenue IntegrityPre- and post-payment review services, clinical editing, and coding analytics designed to recover improper medical billing.The company captures a portion of the healthcare savings it uncovers by catching billing errors for insurers.
Data & Analytics SolutionsSubscription-based intelligence software, risk scoring models, and decision-support platforms like PlanOptix and BenInsights.Insurers and employers pay recurring software and data fees to access Claritev's healthcare cost analytics.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 3.66
Enterprise Value 5.18B
Price to Sales(TTM) 0.45
Enterprise Value 5.18B
Price to Sales(TTM) 0.45
Enterprise Value to Revenue 5.09
Enterprise Value to EBITDA 10.55
Shares Outstanding 17.07M
Shares Floating 6.84M
Shares Outstanding 17.07M
Shares Floating 6.84M
Percent Insiders 7.57
Percent Institutions 88.47

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.